Here’s a collection of video responses from a group of experts at the “Targeted Therapies in Lung Cancer” conference a few weeks ago to the question, “What are the new treatment approaches and agents you’re most optimistic about for potentially becoming clinical tools in the next few years?”.
Drs. Ross Camidge (University of Colorado) and Corey Langer (University of Pennsylvania)
Dr. David Spigel (Sarah Cannon Cancer Center)
Here are a couple of great videos from several experts in lung cancer that describe their approach to the setting of acquired resistance, when a patient with a specific “targetable” mutation who responds well to the relevant treatment in question then develops progression of disease. This is actually a pretty new challenge in lung cancer, and most experts feel that there’s reason to consider some newer approaches.
We’ve been producing video content from the IASLC Targeted Therapies in Lung Cancer conference as quickly as we can. Here are a bunch of additional videos from a range of great experts all around the US, covering many of the most timely topics in targeted therapies for lung cancer today.
I just attended a meeting in Los Angeles, called the 13th Annual International Association for the Study of Lung Cancer (IASLC) Targeted Therapies in Lung Cancer conference. It brings together dozens of leading lung cancer researchers to provide updates to each other and a broader audience of lung cancer community members about the latest new agents and research avenues for clinical research in lung cancer. While there, I had the opportunity to sit down with many of my colleagues, who were kind enough to share their thoughts on many very current issues in the field. Here are the first few of them.
I wanted to start a new video series that will provide illustrative cases from my clinic that introduce broader teaching points. This first video covers the decision-making process that led me to recommend post-operative (adjuvant) chemotherapy for a patient who had a 3.5 cm lung adenocarcinoma resected, and who had no lymph node involvement. We typically recommend chemo only for larger node-negative lung cancers, but her particular cancer had some other features that made me concerned enough about her risk of recurrence to favor at least a good consideration of chemotherapy. Here’s my discussion of some of the variables that are relevant in this setting.
As always, I’d welcome your thoughts, questions, objections, etc., as well as any feedback you want to offer about the format of using clinical cases to review broader concepts. And any ideas for topics are also welcome.
